• Home
    • Leucémie myéloïde chronique
    • Leucemia Mieloide Crónica
  • CML Experts
    • How to get the CMLer's password?
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • CML experts in America >
      • CML experts in Canada >
        • How to get the CMLer's password?
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connie Eaves
        • Dr. Josée Hébert
        • Dr. Vincent Éthier
        • Dr. Marc Lalancette
        • Dr. Luigina Mollica
        • Dr. Dennis Kim
        • Dr. Pierre Laneuville
        • Dr. Pierre Laneuville (v. fr.)
        • Dr. Conrad Vincent Fernandez
        • Dr. Isabelle Bence-Bruckler
        • Dr. Jeffrey H Lipton
        • Dr. Mark Hnatiuk
      • CML experts in US >
        • How to get the CMLer's password?
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • Rey Garcia, RN, BSN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Dr. Charles Schiffer
        • Dr. B. Douglas Smith
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Javier Pinilla-Ibarz
        • Dr. Catriona Jamieson
        • Dr. Arul Chinnaiyan
        • Dr. Ami Patel
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Franziska Michor
        • Dr. Frank Giles
        • Dr. Gabriella Hobbs
        • Dr. Ehab Atallah
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Harry P. Erba
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Matt Kalaycio
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Ellen K. Ritchie
        • Dr. Karen Seiter
        • Dr. Kendra Sweet
        • Dr. Michael Savona
        • Dr. Neil Shah
        • Dr. Richard T Silver
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Ronald L. Paquette
        • Dr. Sangmin Lee
        • Dr. Srinivas K. Tantravahi
        • Dr. Bin Zhang
      • CML experts in South America >
        • Dr. Michele Bianchini
        • Dra Beatriz Moiraghi
        • Dra. Carla Boquimpani
        • Dr Carolina Pavlovsky
    • CML Experts in Europe >
      • CML Expert in Belgium >
        • Pr Gregor Verhoef
      • CML expert in France >
        • Comment obtenir le mot de passe?
        • Dr. François-Xavier Mahon
        • Dr Aude Charbonnier
        • Dr. Agnès Guerci Bresler
        • Dr Pascale Cony-Makhoul
        • Dr. Delphine Rea
        • Dr. Gabriel Etienne
        • Dr. Lawrence Legros
        • Dr. Marie-Joëlle Mozziconacci
        • Dre Célia SALANOUBAT
        • Pr. Mauricette Michallet
        • Dr. François Guilhot
        • Dr. ​Emilie Cayssial
        • Dr Françoise Huguet
        • Dr. Stéphane Prost
        • Dr. Philippe Rousselot
        • Dr. Eliane Gluckman
        • Dr. Franck-Emmanuel Nicolini
      • CML expert in Italy >
        • Dr. Carlo Gambacorti-Passerini
        • Dr. Chiara Elena
        • Dr. Gianantonio Rosti
        • Dr. Massimo Breccia
        • Dr. Michele Baccarani
        • Dr. Giuseppe Saglio
      • CML expert in UK >
        • Dr. Jane Apperley
        • Dr. Richard Clark
        • Dr. Stephen O'Brien
        • Dr. Georgios Nteliopoulos
        • Dr. Adam Mead
        • Dr. Tessa L Holyoake
      • CML expert in Germany >
        • Dr. Andreas Hochhaus
        • Professor Jörg Hasford
        • Professor Oliver Hantschel​
        • Dr Susanne Saussele
        • Dr. Martin Müller
      • CML expert in Portugal >
        • Dr. Antônio Medina de Almeida
      • CML expert in Spain >
        • Dr. Juan Luis Steegmann
      • CML expert in Netherlands >
        • Dr. Jeroen J.W.M. Janssen
      • CML expert in Sweden >
        • Dr. Johan Richter
      • CML expert in Czech Republic >
        • Dr. Hana Klamova
    • CML experts in Asia >
      • Dr. Annuar Rapaee
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Uday Yanamandra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • CML experts in Africa >
      • Dr. Asmaa Quessar
      • Dr. Anthony Oyekunle
    • CML experts in Australia >
      • Dr. Ilaria Pagani
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. David T. Yeung
      • Dr. Liu Lu
      • Dr. Naranie Shanmuganathan
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • How to get the CMLer's password?
    • Introduction to CML >
      • Precision medicine in chronic myeloid leukemia
      • Philadelphia chromosome
      • BCR-ABL Transcripts
      • Sokal, Hasford, and EUTOS scores
    • General concepts >
      • Blood
      • Bone Marrow
      • DNA
      • Electrolytes
      • Stem Cells
      • Immune System >
        • Natural killer cell - NK
        • T Cells
      • Blood-Brain Barrier
    • Clinical Trials
    • Treatment response in CML
    • Resistance to treatment in CML >
      • Molecular monitoring in CML >
        • Polymerase Chain Reaction (PCR)
        • Dr. Kary Bank Mullis
      • Non-adherence of CML patients
      • Sensitive detection of BCR-ABL1 mutations
      • JAK2 Gene
    • Donor lymphocyte infusion (DLI)
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • How to get the CMLer's password?
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Imatinib
    • Tasigna (Nilotinib) >
      • Generic nilotinib
    • Sprycel (Dasatinib) >
      • Generic Dasatinib
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • Scemblix (Asciminib)
    • Tern-701
    • KF1601
    • Synribo (Omacetaxine )
    • HQP1351 (Olverembatinib)
    • Jakafi (Ruxolitinib)
    • K0706 (Vodobatinib)
    • Flumatinib
    • (Bafetinib)
    • Danusertib
    • DCC-2036 (Rebastinib)
    • BGB324
    • PF-114
    • NEV-801
    • ELVN-001
    • BP1001
    • S116836
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • How to get the CMLer's password?
      • Acid Uric - Gout
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Hair
      • Heart
      • Hepatotoxicity
      • Kidney
      • Muscle cramping
      • Night Sweats
      • Peripheral Neuropathy in CML
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Thyroid dysfunction
      • Skin
      • Weight gain
    • CML and Nutrition
    • Food and Drug Interactions
    • CML and comorbidities >
      • Living with CML and diabetes
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Hypnotherapy
      • Music therapy >
        • YouTube creation by CMLer's family
        • Relaxing Music for Stress Relief. Calm Music for Meditation, Sleep, Healing Therapy, Spa
        • Debussy – Relaxing music - Clair de lune et autres...
        • Delicate music for the soul and LIFE, and birdsong soothes the nervous system.
        • Adagio for Strings (Samuel Barber)
        • Amélie Soundtrack ♥ Comptine d'Un Autre Été
        • The song "Disenchanted'
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • How to get the CMLer's password?
    • 30 years and plus survivors >
      • How to get the CMLer's password?
      • Mark Popadick
      • Mary Sullivan
      • Dr. Robert Patenaude -E
      • Skip Duffe
      • Sister Shirley Vaughn
      • Tamera Simonson
    • 20 years and plus survivors >
      • How to get the CMLer's password?
      • Doug Jenson
      • Giora Sharf
      • Joannie Clements
      • Mel Mann
      • Kevin Williams
      • Rich Jones
      • Tanja Fajon
      • Virginia Garner
    • 10 years and plus survivors >
      • How to get the CMLer's password?
      • Dan Sloan
      • Drew Johnston
      • Erin Zammett Ruddy
      • Erin Havel (Author)
      • Gary Gonzales
      • Jan Geissler
      • Jean McGlynn
      • Jo'story
      • ELLE Halliwell (Pregnancy)
      • Kayla Naton (Pregnancy)
      • Leanne
      • Mary Jane Bertram
      • Pat Elliott
      • Rob Shick
      • Tegan Kubler
      • Tom Cleaver
      • Sohag
    • New CMLers >
      • How to get the CMLer's password?
      • Skye Davidson
      • Amanda Steffy
      • Abbi Evans
      • Alyssa
      • Austin Granatowicz
      • Brown Dudley
      • Nigel
      • Katie
      • Kris
      • Ron Robbecke
    • Celebrities with CML >
      • How to get the CMLer's password?
      • Alexa Score
      • Brian Boyle
      • Carlos Carrasco
      • Charlie Schlatter
      • Doris Muramatsu
      • Dr. Richard Rockefeller
      • Greg Lemond
      • Kareem Abdul-Jabar
      • Kelvin Alston
      • Jason Blake
      • Laura Boyd
      • Lee Zeldin
      • Rick Upchurch
      • Roman Reigns
      • Ryan O'Neal
      • Tim Holcomb
    • Suzan Mc Namara and the petition
    • Bud Romine - the first patient
    • Other testimonials
    • Blogs >
      • How to get the CMLer's password?
      • Living with CML
      • Michelle D's Blog
      • Jon's Blog
      • Blogs not recently updated >
        • Access CML Drugs
        • CMKID's blog – Dislodging the bullet - 2012
        • CML Recovery - Stopping KTI -2011
        • Hans's Blog -2012
        • Elizabeth's Blog - my leukemia - 2013journey
        • Elizabeth's Blog - Heart of the rose -2011
        • Joe's Blog - 2012
        • Josh's Blog - 2014
        • Mannan's Blog -2014
        • Ian's Blog -2014
        • Matt's Blog - 2012
        • Matthew's Blog - 2014
        • Michelle's Blog -2012
        • Nayree's Blog -2011
        • Rob's Blog - 2011
  • Global News on CML
    • English - Latest CML News >
      • News -Archives 2023-2022
      • News -Archives 2021-2020
      • News -Archives 2019-2018
      • News - Archives 2017-2016
      • News Archives - 2015-2014
      • News-Archives -2013-2012
      • News - Archives 2011-2001
    • French (Français) - Dernières nouvelles
    • Spanish (Español)-Ultimas noticias
  • Links to other sites, forums and Facebook
    • Sites (English and other languages)
    • Forums (English and other languages)
    • CML on Facebook
    • CML on Twitter
    • Audio Podcast
  • Various topics
    • How to get the CMLer's password?
    • CML patients and the coronavirus
    • You’ve just been diagnosed
    • History of CML
    • CML causes
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • Increased Risk of Secondary Cancers with CML
    • Vaccination of CMLers
    • CML Blast Crisis treatment
    • Bone marrow transplant
    • Stem cells from umbilical cord blood
    • ThINKK (Therapeutic inducers of Natural Killer cell killing)
    • Children with CML
    • CML and pregnancy
    • Mutation T315I
    • Elderly patients with CML
    • Sports with CML
    • CML Awareness Day >
      • Journée mondiale de sensibilisation à la leucémie myéloïde chronique
    • The movie "Dying to Survive"
    • The movie 'The Blue Butterfly"
  • Cure possible for CML?
    • How to get the CMLer's password?
    • Hematopoietic stem cell transplantation using single UM171-expanded cord blood >
      • Greffe de cellules souches de cordon ombilical amplifiées par la molécule UM171
    • Combination of tyrosine kinase inhibitor with other medication >
      • Combinaison of hydroxychloroquine with tyrosine kinase inhibitor
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of insulin sensitizer MSDC-0600K with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of dasatinib plus Nivolumab
      • Combination of Pembrolizumab with tyrosine kinase inhibitor
      • Combination of interferon with tyrosine kinase inhibitor
      • Combination of Venetoclax with tyrosine kinase inhibitor
    • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
    • Inhibition of the protein Ezh2 can cure CML?
    • Inhibition of STAT5 in conjunction with standard TKI therapy
    • PROTAC-mediated Targeted Protein Degradation
    • CML vaccine
    • Can immunotherapy cure leukemia?
    • Could fasting cure chronic myeloid leukemia
    • Chimeric Antigen Receptor T-Cell Therapy
    • Can genetic sequencing help to cure leukemia?
    • Can the new drug CX-5461 cure leukemia?
    • CRISPR-Cas9 gene-editing technique
    • Presence of bcr abl fusion transcripts in healthy individua
    • Math could help cure leukemia
    • Natural Medicine >
      • Possible cure for CML in Fish Oil
      • Betel leaf may help fight CML
      • Feverfew extract (parthenolide)
      • Can dandelions kill cancer?
      • Can curcumin cure leukemia?
  • Treatment-Free remission(TFR)
    • The French trial called STIM (Stop Imatinib)
    • De-escalation of treatment
    • Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients
  • Educational videos (all languages)
    • Educational videos in English
    • Vidéos pédagogiques en français sur la LMC
    • Videos instructivos en español
  • Educational events
  • CML Tool Box (all languages)
    • English tool box >
      • Survey for CMLer who take asciminib
      • Survey for patients who passed TFR (Treatment-Free Remission)
    • French tool box >
      • Sondage pour les patients qui prennent l'asciminib
      • Sondage uniquement auprès des patients ayant réussi le RST( Rémission sans traitement)
    • Spanish tool box >
      • Encuesta_de_medicación_ LMC.html
    • Know your CML
    • My CML
  • CML Glossaries
  • Moral Support
    • Where to get help and support
    • Family support
    • Dances at the Cancer Research Centre
    • I Had Cancer: You are not alone
    • I’m A Doctor With Chronic Illness. Here Are 12 Things I Wish People Knew
    • 23 Nice Things You Can Do for Someone With Cancer
    • Stronger
    • The march toward healing
    • Be happy
  • Professionnel help and literature
    • Dr. Siddhartha Mukherjee
  • Patient Rights
  • New technological advances
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Survey
  • Awards & Recognition
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
    • Hospital Foundations
  • DONATE
    • Faire un don
    • DONAR
  • About us
    • Our mission
    • Contact us >
      • Nous contacter >
        • Contácte nos.
Chronic Myeloid Leukemia

Mutation T315I -   Chronic Myeloid Leukemia-      CML

"Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease. Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib. Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid. This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket. To expedite the identification of strategies to override the resistance imposed by the T315I mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1."
Extract of Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
DRUGS FOR THE T315I MUTATION

Iclusig (Ponatinib)
Scemblix (Asciminib) 
HQP1351 ( Olverembatinib ) 
Synribo (Omacetaxine)
PF-114
DCC-2036 (Rebastinib)
BGB324
​S116836
​
MK0457
KW-2449

ELVN-001
                                                 Attention​ 
To access these modules, you need the CMLer's password called the CMLers's code.   
GET your cmler's password
CLINICAL TRIALS 

KW-2449 by Kyowa Hakko Kirin Pharma, Inc

A Phase II Study of MK0457 in Patients  With T315I Mutant CML and Ph+All  (0457-008)

Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation


                     Other clinical trials with the mutation  T315I
VIDEOS
​

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation (Dr, Jorge Cortes)
January 4, 2021, ecancer


Debate: Chronic-Phase CML Patient Develops a T315I Mutation - Experimental Therapy
June 5, 2019, ImedexCME


Debate: Chronic-Phase CML Patient Develops a T315I Mutation - Transplant
June 5, 2019, ImedexCME

Case 2: Ponatinib for T315I-Mutated CML
June 4, 2019, Targeted Oncology
 
Case 2: Additional Treatment Considerations for T315I-Mutated CML
June 4, 2019, Targeted Oncology


Case 2: Relapsed CML With T315I Mutation
June 4, 2019, Targeted Oncology


What are the sensitivities of different CML therapies to various mutations including T315I? (Dr, Jorge Cortes)?
April 29, 2016, MediCom Oncology

Ponatinib Efficacy and Safety With the T315I Mutation: Long-Term Follow-up of Phase 1&2 Trials (Dr. Michael Mauro)
February 18, 2015, Oncology.TV
ARTICLES

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
May 16, 2024, Leukemia


Activity of First-in-Class STAMP Inhibitor in T315I-Mutated CML
February 1, 2021, JNCCN360


Mutations in the BCR‑ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis
May 20, 2020, Spadidos Publications


Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia
December 11, 2019, PubMed


Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy
December 13, 2019, Dovepress


Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure 
December 12, 2019, The New England Journal of Medicine

Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH" 
December 10, 2019, Biospace

Ascentage Pharma to Release Updated Data of its Novel, Third-Generation BCR-ABL Inhibitor, HQP1351, in Chinese Chronic Myeloid Leukemia Patients in an Oral Presentation at the 61st American Society of Hematology Annual Meeting
November 14, 2019, PrNewswire

Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
July 22, 2019, Biospace

Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study
2018, Blood Journal

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy
December 3, 2018, ASH 2018

Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq
December 2017, Karbala International Journal of Modern Science


Clinical features and outcomes in chronic myeloid leukemia with T315I mutation
July 31, 2017, Cellular Therapy and Transplantation

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
December 7, 2016, PubMed


Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells
2016, Journal Blood
​
Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation
December 7, 2015, OncologyNurseAdvisor

Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH
July 3, 2015, BMC


Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
January 28, 2015,  NCBI

BCR-ABL Point Mutations and  TKI Treatment in CML Patients
July 8, 2014, SciMedCentral

Novel Therapies for T315I-Mutant Chronic Myeloid Leukemia
January 10, 2014, OncLive

The BCR-ABL T315I mutation compromises  survival in chronic phase chronic myelogenous leukemia patients resistant to  tyrosine kinase inhibitors, in a matched pair analysis
May 28, 2013,  Haematologica

Ponatinib thwarts T315I gene mutation in  chronic myeloid leukemia
November 29, 2012, News Medical
         
Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing: Detection of the T315I Mutation in Bone Marrow CD34+ Cells of a Patient with Chronic Myelogenous Leukemia 6 Months Prior to its Emergence in Peripheral Blood
June 1, 2012, PubLMed
Novel potent inhibitor (P2745) of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines (included T315I)
April 2, 2012, AACR Annual Meeting 2012
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa
January 20, 2012, PubMed


Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbour the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survival compared to historical data
June 12 2011, EHA 2011

A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation
April 12, 2011,  Journal of clinical pathology

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
April 12, 2011, Cancer cell

Ariad, MolecularMD Partner on Companion Dx for T315I Mutation
March 28, 2011,  genomeweb

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In  Vitro and In Vivo
March 24, 2011, Clinical Cancer  Research

Phase I Trial Shows Ponatinib May Thwart Most Resistant CML
December 16, 2010,  MD Anderson Cancer Center - Department of Leukemia

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
November 17, 2010, Clinical Cancer Research

The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
November 15, 2010,  Cancer Research

The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge
March 3, 2010, Clinical Lymphoma,  myeloma & Leukemia

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutatedBCR/ABL translocation
May 28, 2009, Journal Blood

ChemGenex's Omacetaxine Demonstrates 80% Complete Hematological Response Rate In Drug-Resistant CML Patients With The T315I Mutation
December 10, 2008,  Medical News Today

Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor
December 8, 2008, ASH2008

Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia

March 6, 2008, Clinical Cancer Research

                  
Our disclaimer       Notre avis de non-responsabilité     Nuestro descargo de responsabilidad
  Privacy Policy              Politique de confidentialité                  Politica de Confidencialidad   
                    
Copyright © 2010-2025 CMLeukemia.com
Protected by Copyscape     DMCA.com Protection Status